Can secondary HLH/MAS be caught before it escalates? Join Fabrizio De Benedetti in our NEW CME-accredited module, “Secondary HLH/MAS Masterclass,” as he unpacks the diagnostic puzzle and explores evolving treatment pathways to improve outcomes #MedX #CME https://t.co/e70Y5aQ4Ff

📰It’s news-day Tuesday! New trial data suggest cannabis outperforms opioids for lower back pain, while a dietary intervention may help heal intestinal damage from radiation or chemotherapy. Read the #news you need to know now, over on Medthority #MedX https://t.co/kHgygH48Pz

From new approaches in alopecia areata (AA) assessment to emerging agents for hidradenitis suppurativa (HS), catch up on the insights you might have missed at this year’s #EADVCongress with our NEW highlights #MedX #Dermatology https://t.co/dJvUIbEBAD

Can early cystoscopy improve #NMIBC survival? A nationwide study suggests yes, with a 42% lower risk of all-cause mortality within 6 months of TURBT. Read our latest news article now for more information, including subgroup analysis and limitations #MedX https://t.co/Guj4RS4mgd

#UEGWeek kicks off this weekend! Stay up to date on the latest insights in gastroenterology with this accredited symposium on #AATD. Earn #CME credit now with expert advice on implementing multidisciplinary care and emerging therapies #MedX #UEGWeek2025 https://t.co/iVpfg3gDdO

Watch Gregory Piazza and Rohan Wijesurendra share their key takeaways from this year’s #ESCCongress, focusing on navigating bleeding risk in patients with provoked VTE and the future of asymptomatic AF screening and diagnosis #MedX #Cardiology https://t.co/7bbsH1sHrg

October is #BreastCancerAwarenessMonth! Get closer to the conversations that matter in breast cancer care with congress highlights and the latest news and guidelines, free and on demand with Medthority #MedX #Oncology #BreastCancer https://t.co/DL8QAoWqcu

How does AATD impact pulmonary health? This #InternationalPodcastDay, tune in to episode 1 of ‘Understanding AATD’ to hear Pavel Strnad and @MiravitllesMarc explore this rare disease’s pulmonary impact, from comorbidities to delayed diagnosis #MedX #CME https://t.co/IQSvUFFhEz

How are thymidine kinase 2 deficiency (TK2d) care strategies evolving? Michio Hirano shares the latest updates on managing TK2d, from early symptom care to emerging disease-modifying therapies, in this accredited on-demand symposium from #EPNS2025 #MedX https://t.co/Tle050gGpY

Is precision medicine redefining #mCRPC care? Visit Medthority now for more on treatment options, their clinical implications, and meeting unmet needs #ProstateCancerAwarenessMonth #ProstateCancer #UrologyAwarenessMonth #MedX https://t.co/hCKcNoenH9

What is Fred Witjes’ top tip for reassuring patients with #NMIBC about life after cystectomy? Listen to Witjes and @UroDocAsh share practical strategies for supporting older, frailer patients through treatment in our expert podcast series #MedX #Oncology https://t.co/w9HaC1B1Ac

Get the latest medical news and updates you need to know, straight to your inbox. Visit our news page or sign up for our regular newsletter, making it even easier to stay up to date #MedX #MedicalNews https://t.co/yVe2VMflvl

What are the key takeaways in #CSU management from #EADVCongress? Catch-up on the updates you need to know, from clinical outcomes in key trials to comparative insights on advanced therapies, with our short summary articles available now #MedX #EADV2025 https://t.co/WDhuJKrVaP

NEW episode: Which studies presented at #ESCCongress showed practice-changing results in thrombosis management? Listen to @GBarnesMD and Marco Prioretti discuss the updates you need to know on venous thromboembolism and atrial fibrillation #MedX #ESC2025 https://t.co/rQGmUMWov3

That’s it for our round-up of one of the many 'Controversies' sessions at this year’s #EADVCongress. For more insights on AA, visit Medthority now for the updates you need to know #EADV2025 #MedX #Dermatology https://t.co/Hclm7Zx5Gq

❓Where do you stand on PRP for alopecia areata? Promising frontier or premature hype? Join the conversation in the comments below #EADVCongress #EADV2025 #MedX #Dermatology

The debate reflected a broader tension in dermatology: innovation vs evidence. PRP is biologically plausible and increasingly popular, but is it ready for prime time in AA? #EADVCongress #EADV2025 #MedX #Dermatology

Sigall emphasized the importance of standardization: dose, purity, activation, and efficiency of PRP prep all impact outcomes. Without consistency, results can vary widely #EADVCongress #EADV2025 #MedX #Dermatology

Rakowska countered with caution, highlighting: 💵 High costs ❗Procedural risks 📄Lack of support in contemporary guidelines Plus, she pointed to British guidance favoring established therapies over PRP #EADVCongress #EADV2025 #MedX #Dermatology

Sigall started by arguing in favor of PRP, citing: 🩸Capillary formation 🩸Improved nutrient delivery 🩸Anti-apoptotic effects These mechanisms may support follicle survival and regrowth in AA #EADVCongress #EADV2025 #MedX #Dermatology